feedback welcome

Clomipramine-fluoxetine

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[checked revision][draft revision]
 
Line 3: Line 3:
| to = fluoxetine  
| to = fluoxetine  
| stop =  
| stop =  
-
* '''Before day 1:''' gradually reduce dosage of clomipramine to a maximum of 50 mg/day.
+
{{stopClomipramine}}
-
* '''Day 1:''' reduce dosage of clomipramine to 25 mg/day.
+
-
* '''Day 8:''' stop dosage of clomipramine.
+
| start =  
| start =  
-
* '''Day 8:''' start administration of fluoxetine in a normal dosage of 20 mg/day.
+
* '''Day 9:''' start administration of fluoxetine in a normal dosage of 20 mg/day.
| info =  
| info =  
-
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
+
* {{theorSS}}
* Fluoxetine and norfluoxetine are inhibitors of CYP2D6 (strong) and CYP3A4 (moderate), which metabolize clomipramine.  
* Fluoxetine and norfluoxetine are inhibitors of CYP2D6 (strong) and CYP3A4 (moderate), which metabolize clomipramine.  
-
{{review}}
 
}}
}}

Current revision as of 10:59, 4 November 2015

Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine
Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine

Switch medication from clomipramine to fluoxetine.

Nietinrijdenbord.png Stop clomipramine
Eenrichtingbord.png Start fluoxetine
Infobord.png More information
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About